AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash

AEON Biopharma, Inc.

2025-Q1 EPS reported $2.28

Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.
Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference; plans BPD Type 2a meeting with FDA in H2 2025.
Cash and equivalents of $10.4M at March 31, 2025; expected to fund operations through Q4 2025 and planned FDA meeting.
NYSE American accepted compliance plan; granted until August 3, 2026 to regain continued listing standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.